Skip to main content

Remote Job Finders (RJF)

Consummate chameleon Amylyx nears regulatory run in obesity surgery complication

After suffering the market withdrawal of its only product, Amylyx is gearing up for a pivotal Phase 3 readout in post-bariatric hypoglycemia. But the company’s driving ethos is still to treat “debilitating, devastating” neurodegenerative diseases, co-CEO Justin Klee told BioSpace.
Scroll to top